Stay updated on Nefecon in Primary IgA Nephropathy: Clinical Trial
Sign up to get notified when there's something new on the Nefecon in Primary IgA Nephropathy: Clinical Trial page.

Latest updates to the Nefecon in Primary IgA Nephropathy: Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe changes are administrative updates: a new Revision: v3.4.2 is listed and an older funding-status notice (3.4.1) was removed. There are no alterations to study details, eligibility, endpoints, or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check21 days agoChange DetectedAdded a site notice about the lapse in government funding and updated the revision to v3.4.1, replacing the former v3.4.0 note. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check28 days agoChange DetectedUI text capitalization updates (e.g., No FEAR Act Data, Last Update Submitted that Met QC Criteria) and the addition of a Show glossary option, along with the new Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 was added, replacing the previous v3.3.3 revision on the page.SummaryDifference0.0%

- Check64 days agoChange DetectedExpanded the Locations list with new sites across multiple regions and removed several entries; page revision updated to v3.3.3.SummaryDifference1%

- Check85 days agoChange DetectedRevision history for study documents shows v3.3.2 added and v3.3.1 removed. These are administrative updates and do not change the study design, eligibility criteria, outcomes, or participant-facing information.SummaryDifference0.0%

Stay in the know with updates to Nefecon in Primary IgA Nephropathy: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nefecon in Primary IgA Nephropathy: Clinical Trial page.